Related Experiment Video
Updated: Feb 15, 2026
08:24
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
Published on: May 25, 2020
7.5K
Cellular Therapeutics for Heart Failure: Focus on Mesenchymal Stem Cells
Amitabh C Pandey1,2, Jordan J Lancaster3, David T Harris4
1Department of Medicine, University of Arizona, Tucson, AZ, USA.
Stem Cells International
|February 3, 2018
Summary
Mesenchymal stem cells (MSCs) show promise for treating heart failure (HF) by promoting cellular repair through paracrine signaling. Clinical trials are investigating MSCs as a novel therapeutic approach for ischemic heart failure.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Cellular Biology
Background:
- Heart failure (HF) is a major cause of hospitalization and mortality worldwide, often resulting from ischemia.
- Current pharmacologic treatments manage symptoms but do not halt progressive cardiac remodeling and fibrosis.
- Cellular therapeutics, particularly Mesenchymal Stem Cells (MSCs), offer a new avenue for improving HF treatment.
Purpose of the Study:
- To review the characteristics of MSCs that make them suitable for cellular therapy in HF.
- To present findings from clinical trials investigating MSCs for treating ischemic heart failure.
Main Methods:
- Review of scientific literature and clinical trial data on MSCs in HF treatment.
- Focus on MSC properties, paracrine signaling mechanisms, and clinical outcomes.
Main Results:
- MSCs promote endogenous repair via paracrine signaling, involving cytokines, chemokines, and adhesion molecules.
- Clinical trials are actively exploring the efficacy of MSCs in patients with ischemic heart failure.
Conclusions:
- MSCs possess unique characteristics that position them as promising cellular therapeutics for HF.
- Further clinical investigation is crucial to fully elucidate and optimize MSC-based therapies for heart failure.
More Related Videos
07:03Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
2.6K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
Related Concept Videos
01:19Mesenchymal Stem Cells
5.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.7K
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
966
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
01:22Heart Failure VI: Adjunct Therapies
402
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K